O c t O b e r 7 - 9 , 2 0 1 3Cité Internationale Universitaire of Paris, France
The leadIng ParTnerIng meeTIng In OPen InnOvaTIOn FOr lIFe SCIenCeS
4th editiOn
www.lifescience-outlook.com/innovationdays
P r e l I m I n a r YP r O g r a m
COnFerenCeS – exhIbITIOn hall – One-On-One ParTnerIng meeTIngS – neTwOrkIng
I N N O V A T I O N D A Y S P R E S E N T A T I O N
Innovation Days Highlights
excellent early-stage networking opportunities
Selected biotechnology companies presentations
Interactive workshops and panels featuring industry experts
State-of-the-art partnering software
International exhibition of major new products and solutions
Innovation Prize awarding ceremony
Who will you meet?
emerging biotech companies
Innovation Prize candidates
academic researchers
Pharmaceutical companies
Institutional representatives
Clusters and bioparks
Investors
P R E l I m I N A R Y P R O G R A m m O N D A Y , O C T O B E R 7 T H , 2 0 1 3
10:15 - 11:00 Plenary session
9:30 - 10:15 Plenary session
9:20 - 9:30 Official Opening and Welcoming introduction to the 4th innovation days
9:00 Registration and Exhibition opening
11:00 - 11:30 networking break
new Pharma Strategies: is Open innovation the name of the game? Collaborative r&d project, Out-license, or Spin-out: best Practices, Success Stories, Challenges
FactsIncreasing pressure to heighten productivity and lower cost has led many pharma companies to completely rethink their r&d and commercialization strategies. Open innovation is a concept that has been on everyone’s lips in the life sciences industry lately. but when coming to putting it into practice how do everyone’s interests align? external resources promise new sources of innovation, but also create new challenges for the r&d and commercial teams tasked with delivering approvable, reimbursable and differentiated products at the end of the development process.
What you will learn “experience sharing”: earn about success stories of Open Innovation models and discuss about collaborative approach and new paths to funding drug discovery and development
due diligence: How to ensure a successful process?
Factsm&a or partnering agreement, product or technology, a biotech company should be prepared to open its doors, books and personnel to a potential partner for full disclosure. especially for large deals, due diligence is a complex commercial, legal and financial analysis that involves many within the biotech company and needs to be well orchestrated. various companies have their own processes in place for how to conduct a due diligence.
What you will learn This workshop will give guidance on what needs to be taken into consideration. how can a biotech company prepare for this process? who needs to be involved? what is the expectation of timing for what needs to be accomplished? what does the pharma side expect to see and what do they not want to see?
Panelists will draw from their due diligence experience and discuss what worked and what did not work so well.
OPENINNOVATION
INNOVATIONSTRATEGY
Zeina AntOUn, Clinical research director, GlaxoSmithKline (Fr) Astrid Maria dAHL, executive business development director, AstraZeneca (gb) Stéphane dHALLUin, director, alliance management, Ucb Pharma SA (be) christophe tHUrieAU, Senior vP scientific affairs - President, ipsen innovation (Fr)
Philip dYKStrA, Partner Transaction Services Pharma, Pricewaterhousecoopers (Fr) evonne SePSiS, managing director, eSc Advisors (US)
P R E l I m I N A R Y P R O G R A m m O N D A Y , O C T O B E R 7 T H , 2 0 1 3
12:30 - 14:00 Lunch
INNOVATION CHAllENGES: In the heart of Innovation, selected biotech companies will present their project in front of a panel of experts. Participants will have 10 minutes to pitch their company, product or technology to the panel. Their presentation will be followed by a Q&a time. Participants will be challenged on the quality and effectiveness of their overall pitch. Perfect training to spark interest for a follow-up meeting with investors or potential partners!
11:30 - 12:30 Keynote session
challenging business Model: Key Facts & Future trends
Factsbiotech and Pharma are effectively becoming one industry - the biopharmaceutical industry - although there's a limit to how far Pharma can go down the biotech route. a Pharma can't copy a biotech's discovery and development methodology too closely and, even if it could, biotech haven't brought a golden aera of productivity that would justify doing so. what will the new business model look like? It will include more types of cooperation. The largest biopharmaceutical companies will be responsible for coordinating and funding federations and consortia. In return they'll get access to more innovation, reduced costs and improved productivity. Smaller biopharmaceutical companies, research institutes and academic medical centers will be responsible for generating original ideas and providing disease biology and platform technologies on a fee-for-service basis.
What you will learn Join this session to review both lessons learned from the implementation of novel r&d and commercialization models.
14:00 - 15:15 INNOVATION CHALLENGES • BIOTECH ELEVATOr PITCH
PHARmA & BIOTECHmARKET INSIGHT
celine bOUQUet, head, global academic alliances, Pharma research & early development, institut roche de recherche et Médecine translationnelle (Fr) Frédéric deSdOUitS, evP head of Corporate business development, acquisitions & market Intelligence, Pierre Fabre (Fr) dogan FidAn, global head, early Stage Products Strategic Unit, Sanofi (Fr) Maria FLOccO, Senior director, head Strategic research Partnerships europe, Pfizer (Fr)
Panel: Alessandro nOSedA, director, Scientific Office & Strategic alliances- r&d, Sigma-tau (Ch)
Selected biotech pitch presentations: nassos ALeviZOPOULOS - Zestagen (Ch) vincenc tUr tUr - Lipopharma (eS)
eXPLOrinG tHe FrOntier FOr OncOLOGY
P R E l I m I N A R Y P R O G R A m m O N D A Y , O C T O B E R 7 T H , 2 0 1 3
16:15 - 16:30 networking break
16:30 - 17:30 Presenting session: innovation Prize Finalists
17:30 - 18:00 innovation Prize ceremony
18:00 - 20:00 ceremony cocktail
Selection criteria: search for Excellence
Scientific quality of Innovation
level of intellectual property
Quality of team
Project feasibility
Chances of success on the market/Investor interest
The Universal biotech Innovation Prize confers visibility to promising innovations and aims at facilitating partnership between public and private stakeholders. It is a unique opportunity to identify promising and innovative projects.The Universal biotech Innovation Prize is open to young innovative companies and to academic researchers on:
15:15 - 16:15 Keynote session
theranostic forum
FactsTheranostic Forum is a part of Innovation days and aims at providing key Pharma and diagnostic makers the guidance required and how to integrate theranostic into existing drug development programs to ensure profitable clinical and commercial strategies.
What you will learn This session will introduce the concept of theranostic and will explore the impact of the search of markers to advance drug development and deliver on the promise of personalized medicine. Finally, the panel will discuss the multitude of opportunities for partnering by small and large companies.
THERANOSTICFORUm
Philippe AnciAn, head of molecular Immunology & biomarkers department, transgene (Fr) Michel FinAnce, Chief executive Officer, theradiag (Fr) Pablo JOrdAn, vP - Companion diagnostics & Personalized medicine, biomerieux (Fr)
P R E l I m I N A R Y P R O G R A m T U E S D A Y , O C T O B E R 8 T H , 2 0 1 3
e-Health and the future of the healthcare system
This key session will be a part of the Innovation days, during which leading international experts within the field of e-health will give an overview of current e-health capabilities and implementation and discuss on how we can expect the ever-increasing use of information and communication technology (ICT) to affect the way health care is delivered in the future. The session will also discuss the evidence required for large-scale investments and policy-level commitment that is necessary to achieve national e-health implementation programs.
11:00 - 11:30 networking break
13:00 - 14:00 Lunch
11:30 - 12:15 Plenary session
12:15 - 13:00 Plenary session
Financing approaches to translate early-stage innovation exploring alternative financing model
Facts
Corporate venturing is becoming one of the most prominent strategies for promoting innovation in biotech, now accounting for a fifth of all deals in the sector. while several traditional venture capital funds are shifting their investment from the early stage financing of biotech, corporate venture from pharmaceutical companies has a strong opportunity to play an increasingly important role. abandoning the traditional corporate posture and rethinking their investments on the long term, corporate ventures are becoming reliable investors contributing to the sustainability of the biotech ecosystem.
What you will learn The new principles that are redefining the shape of corporate venturing in the biotech industry.
Understanding intellectual Property
FactsFor a biotech company, the ultimate goal of intellectual property (IP) is to protect the investment that goes into developing a commercial product. but as products are often many years away from commercialization, there are several ways IP can be exploited to get financing and complementary technologies needed for short-term survival.
What you will learn In this session, we will discuss different ways that biotech companies can leverage value from an IP portfolio.
09:30 - 11:00 Keynote session
INNOVATIONFINANCING
E-HEAlTHFORUm
INNOVATIONmANAGEmENT
Markus GOebeL, managing director, novartis venture Fund (Ch) Pierre-noël LirSAc, Président, cellForcure, (Fr) Antoine PAPierniK, Partner, Strategic Partnering, Sofinnova, (Fr)
bénédicte FArAHMAnd, digital Specialist, Genzyme (Fr) Yves LAvAiL, executive director europe Commercialization excellence, bristol-Myers Squibb (Fr) Lionel reicHArdt, Pharmageek (Fr) benjamin SArdA, director of marketing, Orange Healthcare (Fr)
Philippe becKer, Founding Partner, CPI, ePa, becker & Associés (Fr) Francine Le PécHOn-JOUbert, Partner, Operations division, de Gaulle Fleurance & Associés, (Fr) charlotte retZLer, Senior vice President, Intellectual Property, ipsen (Fr) cécile tHeArd-JALLU, Partner, Operations division, de Gaulle Fleurance & Associés, (Fr)
Selected biotech pitch presentations: tapio JOKinen - Medixine Ltd (Fl) christophe LOrieUX - Santech (Fr)
P R E l I m I N A R Y P R O G R A m T U E S D A Y , O C T O B E R 8 T H , 2 0 1 3
14:00 - 15:15 INNOVATION CHALLENGES • BIOTECH ELEVATOr PITCH
16:15 - 17:30 INNOVATION CHALLENGES • BIOTECH ELEVATOr PITCH
15:15 - 16:00 Plenary session
Market Access and innovation
FactsIn order to launch a successful product, reimbursement needs to be taken into account far earlier in the development lifecycle than in the past. Sourcing adequate Innovation is key to future success.This session will focus on the r&d’s role in sourcing innovation and developing products with a greater probability of market access:
developing by disease area strategy for an unmet clinical or economic need Insights for early feedback on the feasibility of market access for a developing product
What you will learn This panel will deliver provocative views on attempts to formulate recipes to develop a go-to-market strategy by innovation sourcing.
16:00 - 16:15 networking break
17:30 - 18:30 closing networking break
mARKETACCESS
biotech companies’ presentations: binah bAUM - Alma bio therapeutics Gmbh (Il) richard PLeASS - Liverpool School of tropical Medicine (Uk) Francois rieGer - Medimum (Fr)
neW AGentS FOr AUtO-iMMUne diSOrderS
Panel: emmanuelle trAnnOY, associate vP global research, Sanofi Pasteur (Fr) Jeffrey ULMer, global head of external research, novartis vaccines & diagnostics, (US)
Selected biotech pitch presentations: Miguel PrUdenciO - instituto de Medicina Molecular (PT) teresa GOnZALO - Ambiox biotech (eS)
neW trendS in vAccineS And treAtMentS FOr inFectiOUS diSeASeS
Katia FincK, Senior director, head of market access europe & mea, Onyx Pharmaceuticals (Ch) Paolo MOrGeSe, director of research, deerfield institute for Healthcare research (Ch) Ali AZOUGH, head of health economics, Amgen (Uk)
Panel: Ola WinQviSt - Karolinska institute (Sw)
I N N O V A T I O N D A Y S 2 0 1 3 S P O N S O R S
Gold sponsor:
O c t O b e r 7 - 9 , 2 0 1 3Cité Internationale Universitaire of Paris, France
Find OUt MOre...
cOntActS
AbOUt tHe innOvAtiOn dAYS:
www.lifescience-outlook.com
AbOUt tHe innOvAtiOn PriZe:
www.universal-biotech.com
Universal medica Group106, bureaux de la Colline92213 Saint-Cloud • FranCe+33 (0) 1 41 12 27 77
Rafi mardachti, President & [email protected]
Aurélia Ringard, Business [email protected]
